Drug intelligence / Profile preview

PYY1-36

Development stage
Unknown
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intravenous, Experimental Routes Only; Not Approved For Any Indication As A Marketed Drug[9][10]
01

Overview

PYY1-36 is a naturally occurring, full-length (36-amino acid) peptide hormone of the neuropeptide Y family, produced primarily by L-cells in the distal gut (ileum and colon) in response to food intake[2][4][5]. It is one of two major forms of Peptide YY (the other being PYY3-36), and acts as an endogenous ligand for several Y-receptor subtypes including Y1, Y2, Y4, and Y5 receptors[2]. Unlike its truncated form PYY3-36—which selectively activates the neuropeptide Y2 receptor to suppress appetite—PYY1-36 binds with high affinity to all four receptor subtypes. Through these interactions it modulates gastrointestinal motility and secretion (inhibiting gastric acid secretion, gastric emptying, small bowel/colonic chloride secretion), reduces pancreatic exocrine/insulin secretion, promotes natriuresis and elevates blood pressure[2][5]. In the central nervous system it can cross the blood-brain barrier; acting via different receptors it may increase appetite through activation of Y1/Y5 receptors[2]. Research has explored its potential therapeutic use for metabolic disorders such as diabetes due to effects on beta-cell function/survival via NPYR1 activation[6], but clinical studies suggest that unlike PYY3-36 it does not significantly reduce energy intake or induce satiety when administered exogenously in humans[9][10].

Other names
Peptide YY 1-36peptide tyrosine tyrosine 1-36pancreatic peptide YY 1-36
02

Targets

NPY5R (Neuropeptide Y receptor type 5)NPY2R (Neuropeptide Y receptor subtype 2)NPY4R (Neuropeptide Y receptor Y4)NPY1R (Neuropeptide Y receptor Y1)

Beyond the preview

Go deeper on PYY1-36.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PYY1-36.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call